Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Gains from Sales and Divestitures: 2015-2024

  • Catalyst Pharmaceuticals' Gains from Sales and Divestitures was N/A to $364,861 in Q4 2024 from the same period last year, while for Dec 2024 it was $364,861, marking a year-over-year change of. This contributed to the annual value of $364,861 for FY2024, which is N/A change from last year.
  • According to the latest figures from Q4 2024, Catalyst Pharmaceuticals' Gains from Sales and Divestitures is $364,861, which was up 1,268.21% from $26,667 recorded in Q4 2017.
  • In the past 5 years, Catalyst Pharmaceuticals' Gains from Sales and Divestitures registered a high of $364,861 during Q4 2024, and its lowest value of $364,861 during Q4 2024.
  • Its 1-year average for Gains from Sales and Divestitures is $364,861, with a median of $364,861 in 2024.